LifeStance Health Group (NASDAQ:LFST) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

LifeStance Health Group (NASDAQ:LFST) had its price objective raised by investment analysts at JPMorgan Chase & Co. from $8.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 14.58% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Jefferies Financial Group upgraded LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. Barclays boosted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group lifted their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, UBS Group lifted their target price on LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.86.

LifeStance Health Group Trading Down 3.0%

LFST stock traded down $0.25 during midday trading on Thursday, reaching $7.86. 2,099,285 shares of the company traded hands, compared to its average volume of 3,247,903. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.89. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.65 and a current ratio of 1.48. The business has a 50 day moving average of $6.86 and a 200-day moving average of $6.76. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of 130.92 and a beta of 1.20.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. As a group, sell-side analysts expect that LifeStance Health Group will post 0.11 earnings per share for the current fiscal year.

LifeStance Health Group declared that its Board of Directors has approved a share buyback program on Wednesday, February 25th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 3.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Robert Bessler sold 75,000 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $8.55, for a total transaction of $641,250.00. Following the transaction, the director owned 1,236,948 shares of the company’s stock, valued at approximately $10,575,905.40. This represents a 5.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Darren M. Black sold 4,314,939 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $7.01, for a total value of $30,247,722.39. Following the transaction, the director directly owned 29,209,776 shares in the company, valued at $204,760,529.76. The trade was a 12.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 4,464,939 shares of company stock worth $31,417,131. Corporate insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds have recently modified their holdings of the business. Larson Financial Group LLC lifted its position in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the period. KBC Group NV purchased a new stake in shares of LifeStance Health Group in the 1st quarter worth approximately $29,000. Bayesian Capital Management LP purchased a new stake in shares of LifeStance Health Group in the 2nd quarter worth approximately $52,000. PNC Financial Services Group Inc. lifted its position in shares of LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the period. Finally, Assetmark Inc. raised its position in shares of LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after acquiring an additional 1,367 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.